Literature DB >> 25340002

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy.

Yasmin Issa-Nummer1, Sibylle Loibl1, Gunter von Minckwitz1, Carsten Denkert2.   

Abstract

We have prospectively validated in an independent clinical cohort the finding that elevated amounts of tumor-infiltrating lymphocytes in breast carcinoma tissues predict the response of patients to neoadjuvant chemotherapy. These results suggest that a robust tumor infiltration by T and B cells is a promising biomarker to define patients who might benefit from neoadjuvant chemotherapy.

Entities:  

Keywords:  biological marker; breast cancer; neoadjuvant chemotherapy; response predictor

Year:  2014        PMID： 25340002      PMCID： PMC4203634          DOI： 10.4161/onci.27926

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

Review 1.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

2.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Authors:  Sahar M A Mahmoud; Emma Claire Paish; Desmond G Powe; R Douglas Macmillan; Matthew J Grainge; Andrew H S Lee; Ian O Ellis; Andrew R Green
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

3.  Response-guided neoadjuvant chemotherapy for breast cancer.

Authors:  Gunter von Minckwitz; Jens Uwe Blohmer; Serban Dan Costa; Carsten Denkert; Holger Eidtmann; Wolfgang Eiermann; Bernd Gerber; Claus Hanusch; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Sherko Kümmel; Stefan Paepke; Andreas Schneeweiss; Michael Untch; Dirk Michael Zahm; Keyur Mehta; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

Review 4.  Immune parameters affecting the efficacy of chemotherapeutic regimens.

Authors:  Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

5.  Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.

Authors:  Ian C Smith; Steven D Heys; Andrew W Hutcheon; Iain D Miller; Simon Payne; Fiona J Gilbert; Antoinne K Ah-See; Oleg Eremin; Leslie G Walker; Tarun K Sarkar; S Peter Eggleton; Keith N Ogston
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

Review 6.  Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.

Authors:  Fabrice Andre; Maria V Dieci; Peter Dubsky; Christos Sotiriou; Giuseppe Curigliano; Carsten Denkert; Sherene Loi
Journal:  Clin Cancer Res       Date:  2012-12-20       Impact factor: 12.531

7.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

Authors:  Sherene Loi; Nicolas Sirtaine; Fanny Piette; Roberto Salgado; Giuseppe Viale; Françoise Van Eenoo; Ghizlane Rouas; Prudence Francis; John P A Crown; Erika Hitre; Evandro de Azambuja; Emmanuel Quinaux; Angelo Di Leo; Stefan Michiels; Martine J Piccart; Christos Sotiriou
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

8.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Carsten Denkert; Sibylle Loibl; Aurelia Noske; Marc Roller; Berit Maria Müller; Martina Komor; Jan Budczies; Silvia Darb-Esfahani; Ralf Kronenwett; Claus Hanusch; Christian von Törne; Wilko Weichert; Knut Engels; Christine Solbach; Iris Schrader; Manfred Dietel; Gunter von Minckwitz
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

9.  Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.

Authors:  Yasmin Issa-Nummer; Silvia Darb-Esfahani; Sibylle Loibl; Georg Kunz; Valentina Nekljudova; Iris Schrader; Bruno Valentin Sinn; Hans-Ullrich Ulmer; Ralf Kronenwett; Marianne Just; Thorsten Kühn; Kurt Diebold; Michael Untch; Frank Holms; Jens-Uwe Blohmer; Jörg-Olaf Habeck; Manfred Dietel; Friedrich Overkamp; Petra Krabisch; Gunter von Minckwitz; Carsten Denkert
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240
  9 in total
  14 in total

1.  Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy.

Authors:  Marco Galvez; Carlos A Castaneda; Joselyn Sanchez; Miluska Castillo; Lia Pamela Rebaza; Gabriela Calderon; Miguel De La Cruz; Jose Manuel Cotrina; Julio Abugattas; Jorge Dunstan; Henry Guerra; Omar Mejia; Henry L Gomez
Journal:  World J Clin Oncol       Date:  2018-04-10

Review 2.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

3.  Survival after a cancer diagnosis among solid organ transplant recipients in the United States.

Authors:  Monica E D'Arcy; Anna E Coghill; Charles F Lynch; Lori A Koch; Jie Li; Karen S Pawlish; Cyllene R Morris; Chandrika Rao; Eric A Engels
Journal:  Cancer       Date:  2019-01-09       Impact factor: 6.921

4.  Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.

Authors:  E Muraro; E Comaro; R Talamini; E Turchet; G Miolo; S Scalone; L Militello; D Lombardi; S Spazzapan; T Perin; S Massarut; D Crivellari; Riccardo Dolcetti; D Martorelli
Journal:  J Transl Med       Date:  2015-06-27       Impact factor: 5.531

5.  Meta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome.

Authors:  Davide Bedognetti; Ena Wang; Francesco M Marincola
Journal:  Oncoimmunology       Date:  2014-04-09       Impact factor: 8.110

6.  Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Authors:  Magali Michaut; Suet-Feung Chin; Ian Majewski; Tesa M Severson; Tycho Bismeijer; Leanne de Koning; Justine K Peeters; Philip C Schouten; Oscar M Rueda; Astrid J Bosma; Finbarr Tarrant; Yue Fan; Beilei He; Zheng Xue; Lorenza Mittempergher; Roelof J C Kluin; Jeroen Heijmans; Mireille Snel; Bernard Pereira; Andreas Schlicker; Elena Provenzano; Hamid Raza Ali; Alexander Gaber; Gillian O'Hurley; Sophie Lehn; Jettie J F Muris; Jelle Wesseling; Elaine Kay; Stephen John Sammut; Helen A Bardwell; Aurélie S Barbet; Floriane Bard; Caroline Lecerf; Darran P O'Connor; Daniël J Vis; Cyril H Benes; Ultan McDermott; Mathew J Garnett; Iris M Simon; Karin Jirström; Thierry Dubois; Sabine C Linn; William M Gallagher; Lodewyk F A Wessels; Carlos Caldas; Rene Bernards
Journal:  Sci Rep       Date:  2016-01-05       Impact factor: 4.379

7.  Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases.

Authors:  Bettina Sobottka; Bernhard Pestalozzi; Daniel Fink; Holger Moch; Zsuzsanna Varga
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

Review 8.  A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers.

Authors:  George R Nahas; Nykia D Walker; Margarette Bryan; Pranela Rameshwar
Journal:  Breast Cancer (Auckl)       Date:  2015-11-02

9.  Estrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer.

Authors:  Jaime Matta; Luisa Morales; Carmen Ortiz; Damian Adams; Wanda Vargas; Patricia Casbas; Julie Dutil; Miguel Echenique; Erick Suárez
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

10.  Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment.

Authors:  Mariel Garcia-Chagollan; Irma Edith Carranza-Torres; Pilar Carranza-Rosales; Nancy Elena Guzmán-Delgado; Humberto Ramírez-Montoya; María Guadalupe Martínez-Silva; Ignacio Mariscal-Ramirez; Carlos Alfredo Barrón-Gallardo; Ana Laura Pereira-Suárez; Adriana Aguilar-Lemarroy; Luis Felipe Jave-Suárez
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.